The PennZone

  • Home
  • Non-profit
  • Business
  • Education
  • Construction
  • Entertainment
  • Technology
  • Travel
  • Health

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • CCHR Says New OIG Report Raises Concerns about Drugging Elderly with Antipsychotics
  • Philadelphia Community Unites for Awareness 2 Wellness Annual Wellness Fair Focused on Healing, Hope
  • Axencis Launches Performance Partnership for Brand Protection
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • MTV EMA Nominee and WOA Founder Oliver Sean Conferred Doctor of Musical Arts (DMA) Degree
  • Ryan Murphy Joins Personal Injury Law Firm Feldman Shepherd
  • Karen D. Gentry Announces New Book Focused on Relationships and Personal Growth
  • AWARENESS TO WELLNESS: Imhotep Institute Charter High School
  • Colonial Nissan Honors Serge Panchenko for 25 Years of Service

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Boston Industrial Solutions Launches Natron® 717S Series: A New Flexible UV LED Ink for Ricoh GH2220 Printheads
  • 5 Things NYC Courier Services Won't Tell You About How Same-Day Delivery Actually Works
  • Tropidelic Links Up With International Reggae Star Collie Buddz and Eli Mac for Feel-Good Breakthrough Single "Follow Your Nature"
  • Save 15 Percent on Florida Keys Accommodations with KeysCaribbean's 'Advance Purchase Rate Discount'
  • Atelier 411 Studios and Columbus Fashion Council Present Red Carpet Experience at Gateway Film Center for The Devil Wears Prada 2
  • Inclusive Prom "Garden of Glamour" to Celebrate 150+ Special Needs Guests in Bucks County
  • Hazel E Celebrates Birthday with Luxury "Goddess" Yacht Experience in Marina del Rey
  • Joseph Neibich sits down with Bold Jounrey (aka Joseph Nybyk)
  • AI Suite 360 Launches Done-For-You AI Implementation to Rescue SMBs from the "Frankenstein Tax"
  • CX Network Releases Report on the Best AI Support Tools for SaaS Companies 2026
  • Outlier Pest Season Hits Willamette Valley as Mild Winter Drives Early Surge in Ant and Rodent Activity
  • New Bethany Inc. Names Seven New Board Members
  • Lokal Media House Wins Web Excellence Award for Black Plumbing Redesign
  • Who Is Dr. Deshawnda Williams?
  • Lick Expands Flavored Massage Oil Collection with 10 New Indulgent Cream-Inspired Scents
  • 2026 Version of 6-in-1 Estate and Trust Administration Software Released by The Lackner Group
  • Colleen Hanson Recognized for Fourth Consecutive Year by Pennsylvania Business Central
  • New Research Identifies "Vacation Compatibility Gap" as the Hidden Force Shrinking How Long and With Whom Americans Travel
  • Melospeech Inc. Awarded New NYSDOH BEI Contract in New York
  • Five-star Review for Berklee School of Music Textbook

Popular on PennZone

  • Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion - 143
  • 300 Episodes. One Mission: Brother Marcus Ignites a Global Movement of Inspiration - 123
  • R&B Artist Mike Davis Announces Debut Full-Length Album Full Circle, Releasing April 7 - 112
  • The Finger Comb, a Dream Inspired 3-in-1 Styling Tool introduced by Andrea L. Randolph
  • From Speech Therapy to 300+ Episodes: Brother Marcus Turns His Voice Into a Movement Launching a 24/7 Inspiration Radio Network on Day 100 of the Year
  • Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking
  • Mensa Brings National Board Game Competition to Northern Virginia April 16-19
  • Porter's Day Care Empowers Philadelphia's Future Through 45+ Years of Excellence
  • Bishop Mary's WWDB 860 AM Show Nears Historic 250-Episode Milestone
  • Dog Grooming Businesses Turn to Performance-Based Platforms to Attract Local Clients

Similar on PennZone

  • Presidential Acceleration of Psychedelic Therapies Enters a Defining Moment as Federal Policy, FDA Alignment & Breakthrough Neurotechnology Converge
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Charging Into the $30 Billion Heart Failure Market with Late-Stage Momentum, Breakthrough Data, & Strong Financial Backing: Cardiol Therapeutics $CRDL
  • Instant IP Teams: Bringing Enterprise-Grade Collaboration to IP Protection at the Speed of Thought
  • Boston Industrial Solutions Expands Its Industry-Leading UV Ink Portfolio with the Launch of a Matte Ink - Natron® UVPZ
  • AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
  • NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
  • LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
  • Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us